Translate
Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc
MIST · NASDAQ
$2.03USD
0.03 (1.50%)
Press Releases
Market Cap
$178.85 M
Volume
$1.55 M
EPS
-$0.75
Revenue
$1.55 M
About
Milestone Pharmaceuticals Inc (NASDAQ:MIST) — investor relations, events, news, and company updates on 6ix.
Latest News
Feb 10 2026
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
Feb 3 2026
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 26 2026
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Jan 6 2026
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Dec 13 2025
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Financials
Revenue
$1.55 M
Market Cap
$178.85 M
EPS
-0.75